The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant

References

• Carreras E, Diaz-Beya M, Rosinol L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 2011;17:1713-20
   PubMed Web of Science ®Google Scholar
• Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 2010;16:157-68
   PubMed Web of Science ®Google Scholar
• Dvorak CC, Nejadnik B, Cao Z, et al. Hospital cost associated with veno-occlusive disease (VOD) in patients with hematopoietic stem cell transplant (HSCT). Biol Blood Marrow Transpl 2016;22:S275
   Web of Science ®Google Scholar
• Quock T, Zhou Z, Dai B. et al. A model estimating indirect costs of premature death associated with severe hepatic veno-occlusive disease (sVOD) among hematopoietic stem cell tranplant (HSCT) patients in the United States (US). Blood 2015;126:3273
   Web of Science ®Google Scholar
• Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: 2014 CIBMTR Summary Slides. Center for International Blood & Marrow Transplant Research Conference; 2014; http://www.cibmtr.org
   Google Scholar
• Tsirigotis PD, Resnick IB, Avni B, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transpl 2014;49:1389-92
   PubMed Web of Science ®Google Scholar
• Dvorak C, Nejadnik B, Cao Z, et al. Incidence of hepatic veno-occlusive disease (VOD) in premier healthcare database. Blood 2015;126:3280
   Web of Science ®Google Scholar
• Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol 2015;168:481-91
   PubMed Web of Science ®Google Scholar
• Richardson PG, Ho VT, Cutler C, et al. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 2013;19:S88-S90
   PubMed Web of Science ®Google Scholar
• Richardson PG, Ho VT, Cutler C, Glotzbecker B, Antin JH, Soiffer R. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant 2013;19:S88-90
   PubMed Web of Science ®Google Scholar
• Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl 2010;16:1005-17
   PubMed Web of Science ®Google Scholar
• Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 2016;127:1656-65
   PubMed Web of Science ®Google Scholar
• Richardson P, Smith A, Triplett B, et al. Pediatric and adult subgroup results from an ongoing defibrotide expanded access program in the US for patients with hepatic veno-occlusive disease. 20th Congress of Asia-Pacific Blood and Marrow Transplantation Group (APBMT); 2015; Okinawa, Japan
   Google Scholar
• Premier Research Services™ creates insights through data. Premierinc.com: Premier Inc.; 2016. https://www.premierinc.com/transforming-healthcare/healthcare-performance-improvement/premier-research-services/. Accessed November 30, 2016
   Google Scholar
• AnalySource. Analy$ource – Suite of Drug Pricing Services; 2016. https://www.analysource.com/. Accessed November 30, 2015
   Google Scholar
• Manning W, Fryback DG, Weinstein M. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Russell LB, Weinstein M, editors. Cost effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 247-75
   Google Scholar
• Arias E. United States Life Tables, 2009; Natl Vital Stat Rep. 2014;62:1-63
   Google Scholar
• Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011;29:2230-9
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 2012;32:722-32
   PubMed Web of Science ®Google Scholar
• Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general decision models. Comput Biomed Res 1986;19:254-65
   PubMedGoogle Scholar
• Briggs AH, Gray AM. Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making 1998;18:S81-S92
   Web of Science ®Google Scholar
• Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-77
   PubMedGoogle Scholar
• Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998;7:723-40
   PubMed Web of Science ®Google Scholar
• Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002;23:377-401
   PubMed Web of Science ®Google Scholar
• Richardson P, Tomblyn M, Kernan N, et al. Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control. Blood 2009;114:654
   Web of Science ®Google Scholar
• Keating GM. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation. Clin Drug Investig 2014;34:895-904
   PubMed Web of Science ®Google Scholar